For research use only. Not for therapeutic Use.
Salirasib (Cat No.:I002092), also known as Farnesylthiosalicylic acid (FTS), is an experimental anticancer drug that acts as a farnesyltransferase inhibitor. By inhibiting farnesylation, Salirasib disrupts the proper localization and function of Ras proteins, which are commonly activated in cancer cells. This inhibition leads to the disruption of downstream signaling pathways involved in cell proliferation and survival. Salirasib has shown potential in preclinical and clinical studies for various cancers, including pancreatic and lung cancer, by inhibiting tumor growth and inducing apoptosis. Further research is needed to fully evaluate its efficacy and safety.
| Catalog Number | I002092 |
| CAS Number | 162520-00-5 |
| Synonyms | 2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylbenzoic acid |
| Molecular Formula | C22H30O2S |
| Purity | ≥95% |
| Target | MAPK/ERK Pathway |
| Solubility | DMSO: 20 mg/mL |
| Storage | Store at -20°C |
| IUPAC Name | 2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylbenzoic acid |
| InChI | InChI=1S/C22H30O2S/c1-17(2)9-7-10-18(3)11-8-12-19(4)15-16-25-21-14-6-5-13-20(21)22(23)24/h5-6,9,11,13-15H,7-8,10,12,16H2,1-4H3,(H,23,24)/b18-11+,19-15+ |
| InChIKey | WUILNKCFCLNXOK-CFBAGHHKSA-N |
| SMILES | CC(=CCC/C(=C/CC/C(=C/CSC1=CC=CC=C1C(=O)O)/C)/C)C |
| Reference | </br>1:Phase I study of S-trans, trans-farnesylthiosalicylic acid (salirasib), a novel oral RAS inhibitor in patients with refractory hematologic malignancies. Badar T, Cortes JE, Ravandi F, O/’Brien S, Verstovsek S, Garcia-Manero G, Kantarjian H, Borthakur G.Clin Lymphoma Myeloma Leuk. 2015 Jul;15(7):433-438.e2. doi: 10.1016/j.clml.2015.02.018. Epub 2015 Feb 19. PMID: 25795639 Free PMC Article</br>2:Enhancing FTS (Salirasib) efficiency via combinatorial treatment. Wolfson E, Schmukler E, Schokoroy ST, Kloog Y, Pinkas-Kramarski R.Biol Cell. 2015 May;107(5):130-43. doi: 10.1111/boc.201400087. Epub 2015 Apr 21. Review. PMID: 25735913 </br>3:Growth of poorly differentiated endometrial carcinoma is inhibited by combined action of medroxyprogesterone acetate and the Ras inhibitor Salirasib. Faigenbaum R, Haklai R, Ben-Baruch G, Kloog Y.Oncotarget. 2013 Feb;4(2):316-28. PMID: 23530112 Free PMC Article</br>4:Salirasib sensitizes hepatocarcinoma cells to TRAIL-induced apoptosis through DR5 and survivin-dependent mechanisms. Charette N, De Saeger C, Horsmans Y, Leclercq I, Stärkel P.Cell Death Dis. 2013 Jan 24;4:e471. doi: 10.1038/cddis.2012.200. PMID: 23348585 Free PMC Article</br>5:Computer-based identification of a novel LIMK1/2 inhibitor that synergizes with salirasib to destabilize the actin cytoskeleton. Mashiach-Farkash E, Rak R, Elad-Sfadia G, Haklai R, Carmeli S, Kloog Y, Wolfson HJ.Oncotarget. 2012 Jun;3(6):629-39. PMID: 22776759 Free PMC Article</br>6:Integrated preclinical and clinical development of S-trans, trans-Farnesylthiosalicylic Acid (FTS, Salirasib) in pancreatic cancer. Laheru D, Shah P, Rajeshkumar NV, McAllister F, Taylor G, Goldsweig H, Le DT, Donehower R, Jimeno A, Linden S, Zhao M, Song D, Rudek MA, Hidalgo M.Invest New Drugs. 2012 Dec;30(6):2391-9. doi: 10.1007/s10637-012-9818-6. Epub 2012 May 1. PMID: 22547163 Free PMC Article</br>7:A phase II trial of Salirasib in patients with lung adenocarcinomas with KRAS mutations. Riely GJ, Johnson ML, Medina C, Rizvi NA, Miller VA, Kris MG, Pietanza MC, Azzoli CG, Krug LM, Pao W, Ginsberg MS.J Thorac Oncol. 2011 Aug;6(8):1435-7. doi: 10.1097/JTO.0b013e318223c099. PMID: 21847063 Free Article</br>8:Farnesylthiosalicylic acid (salirasib) inhibits Rheb in TSC2-null ELT3 cells: a potential treatment for lymphangioleiomyomatosis. Makovski V, Haklai R, Kloog Y.Int J Cancer. 2012 Mar 15;130(6):1420-9. doi: 10.1002/ijc.26139. Epub 2011 Aug 1. PMID: 21500191 Free Article</br>9:The combined treatment of Copaxone and Salirasib attenuates experimental autoimmune encephalomyelitis (EAE) in mice. Aizman E, Mor A, Chapman J, Assaf Y, Kloog Y.J Neuroimmunol. 2010 Dec 15;229(1-2):192-203. doi: 10.1016/j.jneuroim.2010.08.022. Epub 2010 Sep 24. PMID: 20869125 </br>10:Salirasib inhibits the growth of hepatocarcinoma cell lines in vitro and tumor growth in vivo through ras and mTOR inhibition. Charette N, De Saeger C, Lannoy V, Horsmans Y, Leclercq I, Stärkel P.Mol Cancer. 2010 Sep 22;9:256. doi: 10.1186/1476-4598-9-256. PMID: 20860815 Free PMC Article |
